This is great news, but is there any special considerations for biotech? I have an idea but the minimum investment for a basic prototype instrument will itself eat up this money!
(I work with YC's biotech companies). I'm particularly excited about what this deal means for biotech companies. YC's previous deal of $125K was always a bit light for companies doing wetlab biotech, which is still expensive compared to building software. $500K is a much better fit for the needs of most new biotech companies.
